Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy.
Instituto de Investigacións Tecnolóxicas and Departamento de Física Aplicada, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain.
Adv Mater. 2020 Nov;32(45):e2003712. doi: 10.1002/adma.202003712. Epub 2020 Oct 1.
Nanoparticle-based magnetic hyperthermia is a well-known thermal therapy platform studied to treat solid tumors, but its use for monotherapy is limited due to incomplete tumor eradication at hyperthermia temperature (45 °C). It is often combined with chemotherapy for obtaining a more effective therapeutic outcome. Cubic-shaped cobalt ferrite nanoparticles (Co-Fe NCs) serve as magnetic hyperthermia agents and as a cytotoxic agent due to the known cobalt ion toxicity, allowing the achievement of both heat and cytotoxic effects from a single platform. In addition to this advantage, Co-Fe NCs have the unique ability to form growing chains under an alternating magnetic field (AMF). This unique chain formation, along with the mild hyperthermia and intrinsic cobalt toxicity, leads to complete tumor regression and improved overall survival in an in vivo murine xenograft model, all under clinically approved AMF conditions. Numerical calculations identify magnetic anisotropy as the main Co-Fe NCs' feature to generate such chain formations. This novel combination therapy can improve the effects of magnetic hyperthermia, inaugurating investigation of mechanical behaviors of nanoparticles under AMF, as a new avenue for cancer therapy.
基于纳米颗粒的磁热疗是一种众所周知的热疗平台,用于治疗实体瘤,但由于在热疗温度(45°C)下不完全清除肿瘤,其单药治疗的应用受到限制。它通常与化疗联合使用,以获得更有效的治疗效果。立方体形钴铁氧体纳米颗粒(Co-Fe NCs)既是磁热疗剂,又是细胞毒性剂,因为已知钴离子具有毒性,允许从单个平台实现热和细胞毒性效应。除了这个优势,Co-Fe NCs 还有在交变磁场(AMF)下形成生长链的独特能力。这种独特的链形成,加上温和的热疗和内在的钴毒性,导致在体内异种移植小鼠模型中完全肿瘤消退和整体生存率提高,所有这些都在临床批准的 AMF 条件下进行。数值计算确定磁各向异性是 Co-Fe NCs 产生这种链形成的主要特征。这种新的联合治疗方法可以提高磁热疗的效果,开创了在 AMF 下研究纳米颗粒的机械行为的新途径,为癌症治疗开辟了新途径。
ACS Appl Mater Interfaces. 2019-2-7
Mater Sci Eng C Mater Biol Appl. 2016-3-15
ACS Appl Mater Interfaces. 2020-2-11
Int J Nanomedicine. 2017-8-28
Fundam Res. 2025-1-2
Bioact Mater. 2025-7-26
Eur J Med Res. 2025-6-2
ACS Appl Mater Interfaces. 2025-5-21
Pharmaceutics. 2025-4-9